WO2022246065A1 - Biomarqueur calb1 utilisé dans le traitement de liposarcome dé-différencié à l'aide d'inhibiteurs de xpo1, tels que le sélinexor - Google Patents

Biomarqueur calb1 utilisé dans le traitement de liposarcome dé-différencié à l'aide d'inhibiteurs de xpo1, tels que le sélinexor Download PDF

Info

Publication number
WO2022246065A1
WO2022246065A1 PCT/US2022/030027 US2022030027W WO2022246065A1 WO 2022246065 A1 WO2022246065 A1 WO 2022246065A1 US 2022030027 W US2022030027 W US 2022030027W WO 2022246065 A1 WO2022246065 A1 WO 2022246065A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
hydrogen
alkenyl
carbocyclyl
Prior art date
Application number
PCT/US2022/030027
Other languages
English (en)
Inventor
Christopher Walker
Yosef Landesman
Original Assignee
Karyopharm Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc. filed Critical Karyopharm Therapeutics Inc.
Publication of WO2022246065A1 publication Critical patent/WO2022246065A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de manière générale l'utilisation de modulateurs de transport nucléaire, par exemple, des inhibiteurs de XPO1, tels qu'un composé représenté par la formule structurale (I) : ou un sel pharmaceutiquement acceptable de celui-ci, tel que défini et décrit dans la description, dans un procédé de traitement de liposarcome chez un sujet en ayant besoin.
PCT/US2022/030027 2021-05-19 2022-05-19 Biomarqueur calb1 utilisé dans le traitement de liposarcome dé-différencié à l'aide d'inhibiteurs de xpo1, tels que le sélinexor WO2022246065A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163190526P 2021-05-19 2021-05-19
US63/190,526 2021-05-19

Publications (1)

Publication Number Publication Date
WO2022246065A1 true WO2022246065A1 (fr) 2022-11-24

Family

ID=82016328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/030027 WO2022246065A1 (fr) 2021-05-19 2022-05-19 Biomarqueur calb1 utilisé dans le traitement de liposarcome dé-différencié à l'aide d'inhibiteurs de xpo1, tels que le sélinexor

Country Status (1)

Country Link
WO (1) WO2022246065A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019548A1 (fr) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire contenant de l'hydrazide et leurs utilisations
WO2019233447A1 (fr) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Composés en tant que modulateurs de transport nucléaire et leurs utilisations
WO2020092965A1 (fr) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 en tant que biomarqueur pour des traitements utilisant des inhibiteurs de xpo1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019548A1 (fr) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire contenant de l'hydrazide et leurs utilisations
WO2019233447A1 (fr) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Composés en tant que modulateurs de transport nucléaire et leurs utilisations
WO2020092965A1 (fr) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 en tant que biomarqueur pour des traitements utilisant des inhibiteurs de xpo1

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Nomenclature of Organic Chemistry", 1979, PERGAMON PRESS
BATZER ET AL., NUCLEIC ACID RES., vol. 19, 1991, pages 5081
CASSOL ET AL., MOL. CELL. PROBES, vol. 6, 1992, pages 327 - 331
EISENHAUER EATHERASSE PBOGAERTS J ET AL.: "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1", EUR J CANCER, vol. 45, pages 228 - 47, XP025841550, DOI: 10.1016/j.ejca.2008.10.026
JEITANY MAYA ET AL: "Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 78, no. 4, 26 August 2020 (2020-08-26), pages 1837 - 1851, XP037379459, ISSN: 1420-682X, DOI: 10.1007/S00018-020-03620-W *
OHTSUKA ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 2605 - 2608
ROSSOLINI, MOL. CELL. PROBES, vol. 8, 1994, pages 1119 - 1190
S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
SMITH, M.B.MARCH, J.: "March's Advanced Organic Chemistry", 2001, JOHN WILEY & SONS
THOMAS SORRELL: "Handbook of Chemistry and Physics", 1999, UNIVERSITY SCIENCE BOOKS
WALKER CHRISTOPHER J ET AL: "ASCO Annual Meeting. Molecular predictors of response to selinexor in advanced unresectable de-differentiated liposarcoma (DDLS).", JOURNAL OF CLINICAL ONCOLOGY, vol. 39, no. 15suppl, 28 May 2021 (2021-05-28), pages 11509, XP055946953, Retrieved from the Internet <URL:https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.11509> DOI: https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.11509 *
ZUCO VALENTINA ET AL: "Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 40, no. 1, 1 March 2021 (2021-03-01), XP055946940, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s13046-021-01886-x/fulltext.html> DOI: 10.1186/s13046-021-01886-x *

Similar Documents

Publication Publication Date Title
JP6963146B1 (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
CN101939006B (zh) 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法
WO2021126816A1 (fr) Schéma posologique d&#39;un inhibiteur du kras g12c
CN102740851B (zh) Pi3k抑制剂和mek抑制剂的组合
JP2020158507A6 (ja) 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
CN110402248A (zh) 作为hpk1抑制剂的氮杂吲哚类
JP2020158507A (ja) 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
CN107108611A (zh) 四氢‑吡啶并[3,4‑b]吲哚雌激素受体调节剂及其用途
CN109310754A (zh) 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
CN104363913A (zh) Cdk8/cdk19选择性抑制剂及其在癌症的抗转移和化学预防方法中的用途
CN103582479A (zh) 用pi3k抑制剂化合物治疗间皮瘤的方法
WO2020205409A1 (fr) Liquides ioniques pour l&#39;administration de médicaments
JP2019511554A (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
WO2020092965A1 (fr) E2f1 en tant que biomarqueur pour des traitements utilisant des inhibiteurs de xpo1
Ma et al. IPM712, a vanillin derivative as potential antitumor agents, displays better antitumor activity in colorectal cancers cell lines
CN114901284A (zh) 用细胞周期蛋白依赖性激酶7(cdk7)抑制剂治疗生物标志物鉴定的患者的癌症的方法
WO2019043176A2 (fr) Inhibiteur de l&#39;histone-désacétylase en association avec un agent antimétabolite pour la cancérothérapie
WO2018089967A1 (fr) Inhibiteurs de l&#39;invasion, de la prise et/ou de la métastase du cancer
Guan et al. Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer
JP6063472B2 (ja) 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法
JP2013542965A (ja) 腫瘍の治療方法
JP2008501690A (ja) がんの治療方法
CA3157334A1 (fr) Methodes et compositions pour l&#39;utilisation d&#39;anticorps du facteur de croissance en association avec des inhibiteurs de la kinase de ciblage non-tyrosine
WO2022246065A1 (fr) Biomarqueur calb1 utilisé dans le traitement de liposarcome dé-différencié à l&#39;aide d&#39;inhibiteurs de xpo1, tels que le sélinexor
EP3125901B1 (fr) Dérivés de céphalosporines pour traiter le cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22729394

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE